Ethris develops next-generation mRNA therapeutics and vaccines utilizing proprietary SNIM®RNA and SNaP LNP® platforms for precise delivery. The company focuses on first-in-class mRNA therapeutics to prevent virus-induced exacerbations in asthma and COPD. Their technology also supports the development of mucosal vaccines and protein replacement therapies for rare genetic disorders.
Funding
$11.3M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Current mRNA delivery methods often struggle with immunogenicity, limited potency, and instability, hindering the development of effective mRNA-based therapeutics and vaccines. Traditional approaches also face challenges in achieving targeted delivery to specific organs, particularly the respiratory tract, and often require strict cold-chain logistics.
Solution
Ethris is developing a novel class of mRNA therapeutics and vaccines using its proprietary Stabilized Non-Immunogenic mRNA (SNIM® RNA) and Stablized Lipidoid Nanoparticle (SNaP LNP®) technology platforms. These platforms are designed to generate mRNA molecules with low immunogenicity, high potency, and superior production yields. The technology enables multi-route delivery, including direct administration to the upper and lower respiratory tract via inhalation. Ethris' approach also allows for spray drying, creating stable, dry powder mRNA formulations that eliminate the need for cold-chain logistics, offering a transformative non-invasive treatment strategy for respiratory diseases.
Target Audience
The primary target audience includes patients with respiratory diseases such as uncontrolled asthma and rare genetic disorders, as well as pharmaceutical companies seeking innovative mRNA-based delivery platforms for therapeutic and vaccine development.
Features
- SNIM® RNA platform for generating mRNA molecules with low immunogenicity and high potency
- SNaP LNP® formulation platform for efficient mRNA encapsulation and delivery
- Multi-route delivery platform supporting intramuscular, inhaled, and nasal administration
- Thermostable formulations resistant to mechanical stress, suitable for high-throughput nebulization
- Spray-drying technology enabling stable, dry powder mRNA formulations
- Targeted delivery to the upper and lower respiratory tract